Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||CART22-65s cells + huCART19|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CART22-65s cells||anti-CD22 CAR T cells CART22-65s|anti-CD22 CAR 4-1BB-TCRz CART22-65s||CD22 Immune Cell Therapy 10||CART22-65s cells consist of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD22, and linked to 4-1BB (CD137) co-stimulatory domain and CD3 zeta chain, which potentially induces lysis of tumor cells expressing CD22 (NCI Drug Dictionary).|
|huCART19||huCTL019|CTL119|autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T cells||huCART19 comprise autologous T-cells engineered to express a humanized chimeric antigen receptor (CAR) that targets CD19, as well as CD3zeta chain and 4-1BB, which may result in increased T-cell response against CD19-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03620058||Phase I||CART22-65s cells + huCART19 CART22-65s cells||CART22 Alone or in Combination With huCART19 for ALL||Active, not recruiting||USA||0|